DiabeteK

1560004 Abhishek Adhikari

1560053 Meghna Behera

1560054 Meghna Mohapatra

1560066 Nirakar Panda

1560077 Ramneet Kaur

Problem Statement:
Type 2 diabetes is the most common type of
diabetes. It is a chronic condition in which blood
glucose (sugar) can no longer be regulated. There
are two reasons for this. First, the cells of the body
become resistant to insulin (insulin resistant).
Insulin works like a key to let glucose (blood sugar)
move out of the blood and into the cells where it is
used as fuel for energy. When the cells become
insulin resistant, moving sugar into the cells requires
more and more insulin, and too much sugar stays in
the blood. Over time, if the cells require more and
more insulin, the pancreas can't make enough
insulin to keep up and begins to fail
Innovation Content: DiabeteK
1. What is DiabeteK?
DiabeteK is an encapsulated probiotic obtained from microorganism, Akkermansia muciniphila that reduces the
probability of diabetes without hindering with any other medication.

2. Technical Rationale:
Potential 30 % decrement in diabetes

3. USP (Unique Selling Proposition)

● Ease of production with high recovery with high yield.
● Encapsulation allows the drug to survive the acidic environment and retains the dosage to almost the
ingested concentration promises increased efficacy in relatively less dosages.
● The formulation and packaging as a pump allows easier usage.
● Patentable process
● No such side effects
Technology:
Novel gene obtained from microorganism
Akkermansia muciniphila

Transferred to Probiotic Bacteria

Nano-encapsulation

Inside the gut: produces metabolites which reducing the chances of type 2
diabetes by treating prediabetes: helps maintain the blood sugar at basal levels
 Roadmap
CURRENT STATUS
The developed product: DiabeteK Pre-Market approval by
regulatory bodies
-DBT, Start Up Odisha
-Achieved around 30% at industrial Successfully obtained approval
processing scale level by FDA MARKET
Passed safety and efficacy studies ENTRY
in mice models
1 3

2
Optimization and analysis of Pre-Market Documentation and
reduction by a accredited Intellectual Property filling
testing facility
-PCT
Scale up: Batch of 100 litres

High recovery and downstream

optimization
 Buyer Persona
As per the study carried out by ICMR-
INDIAB study. The patients diagnosed with
Diabetes Type-II were majorly distributed in
the West and South zones, which will be
our initial target zones for the screening
programs.

Heavily distributed through the age group

of age 40 to 79 yrs old.

Making our buyer personas established for

the initial marketing strategies. Prevalence of Type II Diabetes in India in accordance to the
ICMR-INDIAB study
Potential Marketing Strategy
● One owned channel: our own website

01 Branding
● One earned channel through collaboration and
sponsors
● One paid channel

Collaboration with pathologies,

02 labs
●
●
To set up screening centres
Aid to carry out market survey

● With collaboration with company X, free screening

using POC tests
03 Free type 2 screening ●
●
Targeting health fairs, community centres
Followed by follow-up plans by dietitians for better
self-care

04 B2B Marketing ● Targeting the right-physicians

Breakdown of the Funds
Reactors, Heat exchangers, SIP, CIP
15% Plant and Machinery

General Laboratory equipments,

20% Logistics
pipettes, glasswares, columns

30% Internal For conducting research designs

7.5 Travel
Collaborations, setting up screening
centres, networking
%

24% External Services Electricity, rents

3.5 IP Patent filing and consultancy

%